Serum Biomarker of Plaque Vulnerability and Contrast Ultrasound of Carotid Artery

Can Serum Biomarker of Plaque Vulnerability be Identified Through the Contrast-enhanced Ultrasound of Carotid Artery

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01842490

Enrollment

120

Registered

2013-04-29

Start date

2010-05-31

Completion date

2013-12-31

Last updated

2014-08-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Intraplaque Neovascularization Evaluated by Carotid Enhanced Ultrasound Well Reflect the Plaque Vulnerability

Keywords

Biomarker, Carotid enhanced ultrasound, Intraplaque neovascularization

Brief summary

No serum biomarker has qualified for clinical use until now. However several biomarkers, especially markers of inflammatory or proteolytic activity seem to promising in the identification of vulnerable plaques. Moreover, recent study confirmed that contrast-enhanced ultrasound imaging(CEUS) can visualize intraplaque neovascularization and represent the plaque vulnerability. In this study we try to identify indicators through analysis of the relationship between plaque neovascularization seen by CEUS and well known biomarkers such as serum matrix metalloproteinase(MMP)-2, MMP-9, cathepsin family(L,S,V), cystatin C, lipoprotein phospholipase A2, and hs-crp

Interventions

None listed

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* patients with carotid plaques size more than 2mm by carotid ultrasound

Exclusion criteria

* known allergy to albumin, or to the ultrasound contrast agent * the patients with history of carotid endarterectomy and carotid stent * acute myocardial infarction, cardiogenic shock * connective tissue disease and malignancy * creatinine clearance lower than 30ml/min and the history of dialysis

Design outcomes

Primary

Measure	Time frame
Peak plasma concentration of Biomarker that is statistically significant different according to the presence of intraplaque neovascularization on contrast enhanced ultrasound of carotid artery	after performing contrast enhanced ultrasound of carotid artery, upto 3 hospital days

Secondary

Measure	Time frame
the number of the patients with history of cardiovascular event including myocardial infarction, cerebral vascular event and peripheral arterial disease and the number of 1 year clinical outcome of cardiovascular event	after performing contrast enhanced ultrasound of carotid artery, upto 1 year clinical follow up

Countries

South Korea

Outcome results